在摩洛哥的CML患者中出现了新的ABL1突变,该患者患有意马提尼布耐药性
Ihssane El Bouchikhi1, Hajar Azami Idrissi2, Ahmed Lazraq2
1Laboratory of Biomedical & Translational Research, Faculty of Medicine, Pharmacy and Dentistry of Fez, Sidi Mohamed Ben Abdellah University, 30000, Fez, Morocco; Medical Genetics & Oncogenetics Laboratory, Hassan II University Hospital, 30000, Fez, Morocco; Multidisciplinary Laboratory of Research & Innovation, Polydisciplinary Faculty of Khouribga, Sultan Moulay Slimane University, 25000, Kouribga, Morocco.
一种新的BCR::ABL1突变,p.K375M,在慢性髓性白血病 (CML) 患者中引起了对伊马替尼的耐药性. 对个性化CML治疗策略而言,分子研究至关重要.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 慢性髓性白血病 (CML) 是由BCR::ABL1融合基因驱动的.
- 铁氨酸激酶抑制剂 (TKI),像伊马替尼,是有效的CML治疗方法.
- BCR::ABL1突变可能导致对TKI治疗的耐药性.
研究的目的:
- 在CML患者中报告一种新的TKI抗性突变.
- 为了调查发现的突变的致病性.
- 突出分子诊断在CML管理中的重要性.
主要方法:
- 一个摩洛哥CML患者的病例报告,该患者患有二次Imatinib耐药性.
- BCR::ABL1cDNA测序用于识别突变.
- 在基预测和同质分析以评估突变致病性.
主要成果:
- 一个新的突变,在ABL1激酶域中的p.K375M,被确定.
- 在-silico工具预测p.K375M是致病的.
- 突变是保存的,可能会破坏BCR::ABL1-Imatinib的结合,导致耐药性.
结论:
- 这种p.K375M突变扩大了已知的TKI耐药性突变的范围.
- 个性化的CML治疗需要对抗性机制进行分子研究.
- 为了抵抗性,建议切换到第二或第三代TKI.
更多相关视频
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Abnormal Proliferation
